

Second Announcement

17th International Pulmonary Hypertension Forum

ACHIEVE MORE – OPTIMIZING MANAGEMENT IN PAH

**Madrid Marriott Auditorium
Madrid, Spain | 23 – 25 March 2018**

**Scientific Committee:
Professor Marius M. Hoeper
Professor Lewis Rubin**

**Professor Nazzareno Galiè
Professor Vallerie McLaughlin
Professor Gérald Simonneau**



ACTELION

A JANSSEN PHARMACEUTICAL COMPANY
OF *Johnson & Johnson*

Dear Colleague,

As a result of the dedication, research and collaboration within the pulmonary hypertension (PH) community, our understanding of this progressive and debilitating disease continues to increase. Consequently, we are able to offer our patients a range of therapies with proven efficacy alongside evidence-based management approaches, which has changed the outlook for many patients with PH. Now, building on this solid foundation it is possible to take the next step in the optimization of long-term outcomes through the individualization of patient care.

Recently published data have solidified the importance of regular, multi-parameter risk assessment in patients with pulmonary arterial hypertension (PAH). Evidence clearly shows that achieving a low-risk profile has a dramatic impact on the long-term outcomes of patients, underscoring the significance of attaining a low-risk profile as a primary goal of therapy. It is also of paramount importance to act once the risk assessment is performed and intensify the treatment accordingly. In addition, we need to recognize that *'low-risk'* does not mean *'not at risk'* and that these patients can start to show signs of deterioration at any point. It is therefore crucial to remain vigilant and ensure that therapy is escalated at the earliest opportunity, for example via prompt initiation of combination therapy.

Currently available therapies have had a significant impact on disease progression, but despite clear advances there is still a need to investigate additional therapeutic targets. Many potential new avenues for therapeutic investigation continue to be discovered, offering an optimistic outlook for our patients.

This year's Forum will provide an opportunity to discuss these key themes, as well as providing relevant updates on different forms of PH including PH associated with left heart disease, PH associated with lung diseases, and chronic thromboembolic PH (CTEPH).

Targeted breakout sessions will provide information on specialized topics of interest such as updates in clinical trial outcome measures and therapy transition. Patient cases covering a range of PH phenotypes are also included to maximize the sharing of expertise at the Forum. Interactive workshops will provide practical guidance on right heart catheterization and the diagnostic work-up for CTEPH. As in previous years, a nurse-specific program will run alongside the main Forum, highlighting the crucial role that nurses play in the multidisciplinary care of patients with PH.

We are delighted to invite you to the 17th International PH Forum. By coming together to share our experiences, the knowledge shared can be used to drive our understanding forwards for the benefit of all our patients with PH.

Prof. Nazzareno Galiè

Prof. Marius M. Hoeper

Prof. Vallerie McLaughlin

Prof. Lewis Rubin

Prof. Gérald Simonneau

Saturday, 24 March 2018

09:00–10:30 Plenary 1:

Patient assessment today for a better tomorrow

Co-Chairs:
P Escribano, MM Hoyer

- What is coming up in the next two days
- Choosing the right treatment strategy today – A case study
- A paradigm shift in patient assessment
- Disease progression and its impact – A call to action

MM Hoyer
S Bartolome
O Sitbon
V McLaughlin

10:30 – 11:00 Coffee break with poster exhibition

11:00 – 11:45 Interactive debate

Is RHC still a fundamental part of the follow-up assessment in PAH?

Moderator:

- L Howard, M Humbert

R Frantz

11:45 – 12:35 Plenary 2:

Present and future perspectives in PAH management

Co-Chairs:
R Channick, A Frost

- PAH management – State of the art after the 6th WSPH
- Beyond the three pathways – Future targets in PAH

N Galiè
L Rubin

12:35 – 14:00 Lunch

14:00 – 15:15 Parallel breakout sessions:

Managing a complex and multifaceted disease

Co-Chairs:

Case-based learning – A focus on comorbid conditions

S Gibbs

- T Lange, JL Vachiéry, TBC

M Palazzini

From data to insights – Potential new trial endpoints

S Mehta

- R Frantz, S Mehta, A Torbicki

O Sitbon

From right heart failure to end-stage disease

MM Hoyer

- A Frost, J Gottlieb, L Savale

G Simonneau

14:00 – 15:15 Workshop:

RHC in adults

- G Kovacs, S Rosenkranz

Special registration required

15:15 – 15:30 Switching rooms and coffee break

OPTIMIZING MANAGEMENT IN PAH

15:30 – 16:45 Parallel breakout sessions:

Significant progress and pressing issues in PAH

Co-Chairs:

Case-based learning – From pediatrics into adulthood

M Beghetti

- M Beghetti, P Clift, A Manes

B Bouma

Technological innovation in PAH

H Klose

- E Grünig, I Preston, TBC

I Lang

Transitioning therapies – Defining the right patient and the right moment

N Galiè

- A Frost, D Langleben, F Torres

M Humbert

15:30 – 16:45 Workshop:

CTEPH – Diagnostic workup

- R Channick, M Delcroix

Special registration required

Sunday, 25 March 2018

09:00 – 10:35 Plenary 3:

Beyond Group 1 PH – Classification and treatment strategies

Co-Chairs:

JA Barberà, V McLaughlin

- CTEPH – The small vessel component
- Updates in CTEPH management
- PH due to lung diseases – What is new?
- PH due to left heart disease – The right approach

G Simonneau

A Ghofrani

SD Nathan

JL Vachiéry

10:35 – 11:05 Coffee break with poster exhibition

11:05 – 12:40 Plenary 4:

Making connections – Highlights from the field of PAH

Co-Chairs:

M Delcroix, A Torbicki

- PAH-CTD from theory to practice – A patient case
- PAH-CTD – From diagnosis to tailored treatment
- PAH associated with drug use – Where do we stand?
- Highlights of the 17th International PH Forum

G Coghlan

S Gaine

N Kim

R Souza

12:40 – 14:40 Lunch

Abstract submission:

Participants are invited to contribute to the scientific program by submitting abstracts for poster display by Friday, 2 February 2018.

PH Forum Madrid, Spain | 23 – 25 March 2018

Forum Faculty

Joan Albert Barberà Barcelona, Spain	Sean Gaine Dublin, Ireland	Gabor Kovacs Graz, Austria	Lewis Rubin San Diego, USA
Sonja Bartolome Dallas, USA	Nazzareno Galiè Bologna, Italy	Irene Lang Vienna, Austria	Laurent Savale Le Kremlin-Bicêtre, France
Maurice Beghetti Geneva, Switzerland	Ardeschir Ghofrani Giessen, Germany	Tobias Lange Regensburg, Germany	Gérald Simonneau Le Kremlin-Bicêtre, France
Berto Bouma Amsterdam, The Netherlands	Simon Gibbs London, UK	David Langleben Montréal, Canada	Olivier Sitbon Le Kremlin-Bicêtre, France
Richard Channick Boston, USA	Jens Gottlieb Hannover, Germany	Alessandra Manes Bologna, Italy	Rogério Souza São Paulo, Brazil
Paul Clift Birmingham, UK	Ekkehard Grünig Heidelberg, Germany	Vallerie McLaughlin Ann Arbor, USA	Adam Torbicki Otwock, Poland
Gerry Coghlan London, UK	Marius M. Hoepfer Hannover, Germany	Sanjay Mehta London, Canada	Fernando Torres Dallas, USA
Marion Delcroix Leuven, Belgium	Luke Howard London, UK	Steven D. Nathan Falls Church, USA	Jean-Luc Vachiéry Brussels, Belgium
Pilar Escribano Madrid, Spain	Marc Humbert Le Kremlin-Bicêtre, France	Massimiliano Palazzini Bologna, Italy	
Robert Frantz Rochester, USA	Nick Kim San Diego, USA	Ioana Preston Boston, USA	
Adaani Frost Houston, USA	Hans Klose Hamburg, Germany	Stephan Rosenkranz Cologne, Germany	



ACTELION

A JANSSEN PHARMACEUTICAL COMPANY
OF *Johnson & Johnson*

This meeting is sponsored and organised by Actelion Pharmaceuticals Ltd
Actelion Pharmaceuticals Ltd | Gewerbestrasse 16 | 4123 Allschwil | Switzerland
Phone +41 61 565 65 65 | Fax +41 61 565 65 00 | www.actelion.com